Chapter 205 New Antibiotics

Andres Technology, in Chen Yang's positioning, is a company involving high-tech and cutting-edge biotechnology. Although everything is still in its infancy, it has a start-up capital of one billion US dollars. Fang Ye and the others are directly in the downtown business district. , a certain building rented a three-story building as the company's office location.

Of course, the real research center is still located in the suburbs of Los Angeles, the pharmaceutical factory that was purchased and being renovated and built.

"This is Dr. Gerry Foyle, Dr. Gordon Freeman and Dr. Dagenham Hills..."

Everyone walked into the company's conference room, where three employed biomedical doctors stood up together, and Fang Ye quickly introduced them to Chen Yang.

Chen Yang stretched out his hand and shook hands with the three doctors one after another.

In fact, these three doctors were chosen by Chen Yang, so how could he not know these three people?

Dr. Greg Foyle, 45 years old, used to work for Merck. Later, he was fired by the company due to a certain medical error. He is now at a low point in his life. He has divorced his wife and has not fought for it. When it comes to custody of several children, even the personal financial situation is very embarrassing.

Therefore, Andres was just a new company, but the generous remuneration made Foyle agree without hesitation.

The other two, Dr. Freeman and Dr. Hills, were very worried about their financial situation. It was for this reason that they had to agree to Andres' employment under the tremendous pressure of life.

In this world, it does not mean that talents can truly be reused and develop their talents. Let alone talents, even many geniuses have suffered a series of deeply regrettable consequences due to various reasons. matter.

These three doctors all have certain talents, but unfortunately they are not very lucky. If they hadn't met Chen Yang and took a fancy to them, they would probably have wasted their lives.

"Three doctors, I am very glad that you can accept the employment of our company."

Chen Yang spoke fluent English, and everyone present except Wang Rui, who was at a loss, could understand clearly.

Sitting down on the chair, Chen Yang smiled slightly: "I know the three doctors. In fact, I am not very willing to accept the company's employment. I think we are just a new company without much technology. Here, I can ask the three doctors To disclose, in fact, our company is not without technology, but only needs to transform technology into actual talents.”

After saying these words, Chen Yang glanced at Liu Helan. Liu Helan nodded, took out the silver-white password box and opened it. He took out five documents and handed them to everyone present.

"This is……"

Foyle and the other three doctors took the document in confusion and started reading it casually.

After just reading one page, the expressions on the three people's faces changed from the initial casualness to seriousness. The speed of flipping through the documents with their fingers suddenly slowed down, like a priest holding a Bible. Read almost word for word.

Chen Yang was very patient and sipped the coffee on the table. I waited patiently for the three doctors to read, without any hint of impatience.

The three doctors of biomedicine could understand it. Fang Ye and Feng Li's English was not good enough to browse the medical terminology without any obstacles. They quickly flipped through a few pages and put it down in a daze.

Half an hour passed. The coffee was changed three times, and the three doctors finally finished reading the documents.

After reading this, Dr. Foyle asked impatiently: "Where did this information come from?"

"Where did it come from?"

Chen Yang didn't mind Foyle's distrust and said with a smile: "I have said before that the company is not behind other pharmaceutical companies in terms of technology. What it lacks is just talents like three doctors."

What he said was contradictory. Since there is a shortage of talents, where will the technology come from?

Since there is technology, there is certainly no shortage of talent.

The three doctors only thought that Chen Yang was being polite and did not take it seriously. However, judging from their experience, the authenticity of the data stated in this document was very high. It was almost impossible to make it up. Just wait. The clinical trial has entered FDA review.

"If the information on this is true, no, it is indeed correct, then the benefits are obvious."

Hills said solemnly: "Everyone should know that recently the President's Council of Advisors on Science and Technology (pcast) has recommended that the government take measures to speed up research on new antibiotics, and recommended that the FDA establish a special green fast track for the approval of this type of drugs. , to ensure that it can be launched as soon as possible.”

"In this way, we can catch up with the opportunity and get strong support from the government."

The most famous representative of antibiotics is penicillin. Since its birth in 1928, it has traveled nearly a century and saved thousands of lives. It can be said to be famous.

However, due to the extensive misuse of antibiotics, some bacteria have become increasingly resistant to antibiotics, rendering many antibiotics useless.

This situation began in the 1990s and has intensified in the past two decades. This has left many biopharmaceutical companies with far less time to develop new antibiotics than the time it takes for bacterial resistance to develop, resulting in research and development costs that cannot make ends meet.

This situation reached its peak in the late 1990s and early 21st century, when many biomedical giants gave up on the research and development of antibiotics.

But giving up research does not mean that bacterial resistance will not develop.

On the contrary, in recent years, many highly resistant bacteria have increased dramatically, causing many diseases that were originally under control to spiral out of control.

For example, superbinding bacilli have caused the tuberculosis control situation in many developing countries to deteriorate.

If we continue to ignore this issue, I believe that within a few years, many doctors will be horrified to discover that no matter how many units of antibiotics are used, they will have no effect on certain super-resistant bacteria.

As a result, the mortality rate of human beings from contracting the disease will be greatly increased.

Therefore, under this huge future crisis, which has also attracted the attention of the Obama administration, this will be a very big opportunity.

Generally speaking, the faster review process of a new drug takes seven or eight months, and if it is slower, it may even take several years. This time, with the support of the US government in Washington, both the speed and related costs will be greatly reduced.

These are not the most important things. Get ahead of other biopharmaceutical companies and get the recognition of the government. Then you don’t have to worry about advertising and public relations promotion.

With government support and recognition, think about it, how many hospitals are there in the United States? What about other countries?

You know, seven of the world's top ten pharmaceutical companies are in the United States. With government support, it will be more conducive to promoting new antibiotics in other countries.

Money, countless money.

Chen Yang raised his finger on the table and said: "Dr. Hills said it right, and I agree with this point, so we must seize this opportunity. The opportunity is urgent, and we must do it before other pharmaceutical companies launch new antibiotics. Launch our antibiotics first!”

Even with cheating tools like a civilized heart and his right hand, Chen Yang did not dare to ignore those super multinational pharmaceutical companies with tens of thousands of researchers, the most advanced research equipment, the most top biological talents, and the most abundant research funds. As long as they make up their mind and gather strength, apart from those unresolved terminal illnesses, there really won't be many difficulties that can stop them.

Therefore, the top priority is to seize the time to produce new antibiotics and successfully pass government approval.

It is also the first step to make Andres’ name known.

This research material gave Hills and the other three people great confidence. Eating and waiting to die and working hard were two completely different mental states. Now that they knew that this new company was not simple, the three of them felt that A lot more settled.

Although Fang Ye and Feng Li did not know much about biomedicine, Chen Yang explained it clearly enough in the discussion with the three doctors, and they also knew the business opportunities and potential contained in it.

Once you get the hang of it, it's a big deal.

Andres's start-up capital is only US$1.2 billion, of which US$500 million needs to be invested in Australia, and the North American branch will receive US$700 million.

It may seem like a huge number, but in fact, in terms of medical development, it’s hard to describe it as stretched thin. It can only be said to be a fart.

After the pharmaceutical company Eli Lilly invested more than one billion US dollars to develop a new drug and failed, it invested another US$500 million to continue development, but the success rate of the new drug was only 9%.

700 million US dollars to buy land, buy land, buy a small pharmaceutical factory, build several office buildings, and produce new drugs...

Chen Yang could imagine that a month later, Ye Ye and Feng Li would come together to ask for money.

As for the other chess piece Tianqi Technology Company, although it is expected to have profits of more than one billion US dollars in the next year, the earliest sum of money, which is at most several hundred million US dollars, is still far from enough.

Thinking of this, Chen Yang frowned and said: "Dr. Foyle, what do you think the annual sales of this new antibiotic will be after it is launched?"

Although Foyle is a scientist, he has also worked at Merck and is well aware of the sales and potential of some new drugs. When he heard Chen Yang's question, he lowered his head and thought for a moment, then raised his head and said: "According to the information in this document, According to the data, this new antibiotic has a wide range of uses, and its annual sales potential should be between more than 2 billion US dollars and 3 billion US dollars."

Chen Yang nodded. This number is no longer a small number. For example, the well-known amoxicillin was first successfully developed by the British company Beecham. Its annual sales in the world market are only about 1.7 billion US dollars.

If it really has annual sales of more than two billion US dollars, it will truly be the king of antibiotics.

However, such a road is obviously very long, and it is not so easy and smooth to complete. (To be continued...)